HELP – A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction (PHHFpEF)

This study looks for patients who have been diagnosed with pulmonary hypertension secondary to heart failure with normal ejection fraction. The study looks at an investigational medication to improve the symptoms of these conditions. Participants must be 18 years or older, perform a 6-minute walk test of at least 300 feet, and be on a stable dose of all medications for at least 30 days.